A groundbreaking stem cell therapy offers new hope for type 1 diabetes, with early results showing potential for insulin ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

No safety issues were reported, and HIP-modified islet cells evaded immune responses without immunosuppression. The study was conducted in partnership with Uppsala University Hospital. Results of ...

The Seattle-based biotech is evaluating UP421, a donor-derived allogeneic primary islet cell therapy, as a type 1 diabetes treatment that doesn’t require the use of any immunosuppression.

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...

The study identified no safety issues, and the HIP-modified islet cells evaded immune responses. “These initial exciting results build upon the extensive preclinical and translational studies of ...